AbbVie
(NY:
ABBV
)
196.31
+1.13 (+0.58%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,820,805
Open
195.25
Bid (Size)
193.95 (1)
Ask (Size)
196.90 (8)
Prev. Close
195.18
Today's Range
194.17 - 196.50
52wk Range
135.85 - 198.30
Shares Outstanding
N/A
Dividend Yield
3.02%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer
Today 5:53 EDT
A drugmaker and a telecom business have what it takes to safely boost your passive income stream.
Via
The Motley Fool
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Performance
YTD
+22.83%
+22.83%
1 Month
+3.48%
+3.48%
3 Month
+22.55%
+22.55%
6 Month
+10.88%
+10.88%
1 Year
+32.46%
+32.46%
More News
Read More
2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher
August 30, 2024
Via
The Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
August 30, 2024
Via
The Motley Fool
AbbVie Options Trading: A Deep Dive into Market Sentiment
August 29, 2024
Via
Benzinga
AbbVie Unusual Options Activity For August 26
August 26, 2024
Via
Benzinga
Key Takeaways From AbbVie Analyst Ratings
August 23, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
August 20, 2024
Via
Benzinga
2 Incredibly Cheap Healthcare Stocks to Buy Now
August 30, 2024
Via
The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
Via
Talk Markets
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
August 29, 2024
Via
The Motley Fool
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
Via
Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
August 20, 2024
Via
Benzinga
3 Best Growth Stocks to Own for the Next 10 Years
August 28, 2024
Via
MarketBeat
Topics
Economy
Exposures
Economy
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
August 28, 2024
Via
The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Via
Benzinga
Donald Trump Owns These 21 Dividend Kings. Should You?
August 26, 2024
Via
The Motley Fool
Topics
Government
Exposures
Political
3 Unstoppable Dividend Stocks to Buy Right Now
August 25, 2024
Via
The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Via
Benzinga
How To Build A Dividend Growth Portfolio In An Overpriced Market
August 22, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More
August 18, 2024
Via
The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
August 18, 2024
Via
The Motley Fool
3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income
August 17, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.